Experimental REV-ERB-related small molecule · Fact sheet
SR9009
Also known as Stenabolic
SR9009 is a laboratory small molecule investigated in circadian and metabolic models. Some effects persist without REV-ERB receptors, complicating its proposed mechanism; human performance benefit and a safe regimen are unestablished.
What is SR9009?
REV-ERB receptors link circadian regulation and metabolism. SR9009 is frequently used as a research probe.
SR9009 is not a SARM or a peptide, despite being grouped with them in performance discussions.
Benefits & claims
Interest includes performance or metabolic effects, but a mechanism, hormone change or lean-mass result does not establish safe improvement in athletic function.
What the evidence supports
- Early synthetic-ligand work changed circadian and metabolic patterns in mice.
- SR9009 altered viability and metabolism in cells lacking both REV-ERB proteins.
- Mechanistic uncertainty and absent established human outcomes prevent a valid endurance or fat-loss claim.
Research areas
- Performance-related biology
- Clinical or preclinical disease research
Dosage & frequency
No established human regimenThe reviewed sources do not establish a human treatment amount or frequency for SR9009. Animal and laboratory exposures are not human regimens.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- REV-ERB receptors link circadian regulation and metabolism. SR9009 is frequently used as a research probe.
Formulation differences
- SR9009 is not a SARM or a peptide, despite being grouped with them in performance discussions.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Long-term clinically meaningful benefit
- Endocrine, cardiovascular and organ safety
- Identity, exposure and interaction differences outside research settings
Side effects & risks
- Changes in cell viability and off-target activity are unresolved safety considerations.
- Human bioavailability, chronic organ effects and interactions are not established by rodent experiments.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Limited or unclear evidencePrimary evidence includes mouse studies and receptor-deletion cell experiments. The latter show that SR9009 effects cannot be treated as a specific readout of REV-ERB activity.
Studies
Original synthetic REV-ERB ligand experiments in mice.
Receptor-deletion study demonstrating REV-ERB-independent effects.
Mouse cardiac-injury study, not human performance evidence.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
SR9009 has no FDA-approved therapeutic product. The cited research does not establish an approved performance-enhancement use.
Preclinical evidence; no FDA-approved product
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Long-term clinically meaningful benefit
- Endocrine, cardiovascular and organ safety
- Identity, exposure and interaction differences outside research settings
Summary
Mechanistic uncertainty and absent established human outcomes prevent a valid endurance or fat-loss claim.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedRegulation of circadian behaviour and metabolism by synthetic REV-ERB agonists.
Original synthetic REV-ERB ligand experiments in mice.
- pubmedSR9009 has REV-ERB-independent effects on cell proliferation and metabolism.
Receptor-deletion study demonstrating REV-ERB-independent effects.
- pubmedSR9009 administered for one day after myocardial ischemia-reperfusion prevents heart failure in mice by targeting the cardiac inflammasome.
Mouse cardiac-injury study, not human performance evidence.